-
公开(公告)号:US20100280023A1
公开(公告)日:2010-11-04
申请号:US11917972
申请日:2006-06-23
IPC分类号: A61K31/537 , A61K31/427 , C07D417/14 , A61K31/5377 , A61K31/4439 , A61P25/00 , A61P25/16 , A61P25/28 , A61P25/24 , A61P9/10
CPC分类号: C07D491/08 , C07D417/04 , C07D417/14 , C07D493/08 , C07D493/10
摘要: It is intended to provide an adenosine A2A receptor antagonist containing as an active ingredient a thiazole derivative represented by the general formula (I) [in the formula, R1 represents a substituted or unsubstituted five-membered aromatic heterocyclic group containing at least one oxygen atom, R2 represents a substituted or unsubstituted heterocyclic group, —COR6 (in the formula, R6 represents a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group or the like) or the like, R3 represents the general formula (II), —NHCOR (in the formula, R7 represents —NR8R9 or the like) or the like], or a pharmacologically acceptable salt thereof, etc. (I) (II)
摘要翻译: 本发明提供一种含有作为活性成分的通式(I)表示的噻唑衍生物的腺苷A 2A受体拮抗剂[式中,R 1表示取代或未取代的含有至少一个氧原子的5元芳族杂环基, R2表示取代或未取代的杂环基,-COR6(式中,R6表示取代或未取代的杂环基,取代或未取代的芳香族杂环基等)等,R3表示通式(II), - NHCOR(式中,R7表示-NR8R9等)或其药理学上可接受的盐等。(I)(II)
-
公开(公告)号:US20110105486A1
公开(公告)日:2011-05-05
申请号:US12960937
申请日:2010-12-06
申请人: Takao Nakajima , Masamori Sugawara , Shin-ichi Uchida , Tetsuji Ohno , Yuji Nomoto , Noriaki Uesaka , Yoshisuke Nakasato
发明人: Takao Nakajima , Masamori Sugawara , Shin-ichi Uchida , Tetsuji Ohno , Yuji Nomoto , Noriaki Uesaka , Yoshisuke Nakasato
IPC分类号: A61K31/541 , C07D277/38 , C07D417/14 , C07D401/14 , C07D213/89 , C07D413/14 , C07D279/12 , A61K31/426 , A61K31/4439 , A61K31/454 , A61K31/5377 , A61P25/28 , A61P25/00 , A61P3/10 , A61P25/12 , A61P25/24
CPC分类号: C07D417/06 , A61K31/427 , A61K31/438 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/5383 , A61K31/541 , A61K31/542 , A61K31/551 , A61K31/553 , A61K31/695 , C07D417/04 , C07D417/14 , C07D491/048 , C07D491/10 , C07D498/04 , C07D513/04
摘要: Wherein n is an integer of from 0 to 3; R1A is a 5-membered aromatic heterocyclic group containing at least one oxygen atom; R2A is —COR8 (wherein R8 is aryl); R3A is hydrogen or lower alkyl; and R12 represents cycloalkyl, aryl, aralkyl, alicyclic heterocyclic group, aromatic heterocyclic group, alicyclic hetocyclic-alkyl, or aromatic heterocyclic-alkyl, and R1A, R2A, R3A and R12 are individually optionally substituted.
摘要翻译: 其中n为0至3的整数; R1A是含有至少一个氧原子的5元芳族杂环基; R2A是-COR8(其中R8是芳基); R3A是氢或低级烷基; R 12表示环烷基,芳基,芳烷基,脂环族杂环基,芳香族杂环基,脂环族环状烷基或芳香族杂环烷基,R1A,R2A,R3A,R12分别任意取代。
-
公开(公告)号:US20100256361A1
公开(公告)日:2010-10-07
申请号:US12766986
申请日:2010-04-26
申请人: Takao Nakajima , Masamori Sugawara , Shin-ichi Uchida , Tetsuji Ohno , Yuji Nomoto , Noriaki Uesaka , Yoshisuke Nakasato
发明人: Takao Nakajima , Masamori Sugawara , Shin-ichi Uchida , Tetsuji Ohno , Yuji Nomoto , Noriaki Uesaka , Yoshisuke Nakasato
IPC分类号: C07D417/14 , C07D413/14 , C07D498/04
CPC分类号: C07D417/06 , A61K31/427 , A61K31/438 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/5383 , A61K31/541 , A61K31/542 , A61K31/551 , A61K31/553 , A61K31/695 , C07D417/04 , C07D417/14 , C07D491/048 , C07D491/10 , C07D498/04 , C07D513/04
摘要: (Wherein n is an integer of from 0 to 3; R1 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, or a substituted or unsubstituted aromatic heterocyclic group; R2 is halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, —COR8, or the like; R3 and R4 may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, —COR12, or the like)For example, provided are adenosine A2A receptor antagonists comprising, as the active ingredient, a thiazole derivative represented by a general formula (I), or a pharmaceutically acceptable salt thereof, and the like.
摘要翻译: (其中n为0〜3的整数; R 1为取代或未取代的环烷基,取代或未取代的芳基,取代或未取代的脂环族杂环基或取代或未取代的芳香族杂环基; R2为卤素,取代或未取代的低级烷基 取代或未取代的芳基,取代或未取代的脂环族杂环基,取代或未取代的芳族杂环基,-COR 8等; R 3和R 4可以相同或不同,表示氢原子,取代或未取代的低级 烷基,取代或未取代的芳烷基,-COR 12等)例如,提供的是腺苷A 2A受体拮抗剂,其包含作为活性成分的由通式(I)表示的噻唑衍生物或其药学上可接受的盐,以及 类似。
-
公开(公告)号:US07718808B2
公开(公告)日:2010-05-18
申请号:US10584633
申请日:2004-12-24
申请人: Takao Nakajima , Masamori Sugawara , Shin-ichi Uchida , Tetsuji Ohno , Yuji Nomoto , Noriaki Uesaka , Yoshisuke Nakasato
发明人: Takao Nakajima , Masamori Sugawara , Shin-ichi Uchida , Tetsuji Ohno , Yuji Nomoto , Noriaki Uesaka , Yoshisuke Nakasato
IPC分类号: A61K31/427 , C07D417/14
CPC分类号: C07D417/06 , A61K31/427 , A61K31/438 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/5383 , A61K31/541 , A61K31/542 , A61K31/551 , A61K31/553 , A61K31/695 , C07D417/04 , C07D417/14 , C07D491/048 , C07D491/10 , C07D498/04 , C07D513/04
摘要: (Wherein n is an integer of from 0 to 3; R1 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, or a substituted or unsubstituted aromatic heterocyclic group; R2 is halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, —COR8, or the like; R3 and R4 may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, —COR12, or the like)For example, provided are adenosine A2A receptor antagonists comprising, as the active ingredient, a thiazole derivative represented by a general formula (I), or a pharmaceutically acceptable salt thereof, and the like.
摘要翻译: 本发明提供的腺苷A 2A受体拮抗剂包含作为活性成分的由通式(I)表示的噻唑衍生物或其药学上可接受的盐:......(其中n为0-3的整数; R 1为取代或 取代或未取代的芳基,取代或未取代的脂环族杂环基或取代或未取代的芳族杂环基; R2为卤素,取代或未取代的低级烷基,取代或未取代的芳基,取代或未取代的脂环族杂环基, 或未取代的芳族杂环基,-COR 8等; R 3和R 4可以相同或不同,各自表示氢原子,取代或未取代的低级烷基,取代或未取代的芳烷基,-COR 12等)。
-
公开(公告)号:US08420827B2
公开(公告)日:2013-04-16
申请号:US12960937
申请日:2010-12-06
申请人: Takao Nakajima , Masamori Sugawara , Shin-ichi Uchida , Tetsuji Ohno , Yuji Nomoto , Noriaki Uesaka , Yoshisuke Nakasato
发明人: Takao Nakajima , Masamori Sugawara , Shin-ichi Uchida , Tetsuji Ohno , Yuji Nomoto , Noriaki Uesaka , Yoshisuke Nakasato
IPC分类号: A61K31/427 , C07D417/14
CPC分类号: C07D417/06 , A61K31/427 , A61K31/438 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/5383 , A61K31/541 , A61K31/542 , A61K31/551 , A61K31/553 , A61K31/695 , C07D417/04 , C07D417/14 , C07D491/048 , C07D491/10 , C07D498/04 , C07D513/04
摘要: Wherein n is an integer of from 0 to 3; R1A is a 5-membered aromatic heterocyclic group containing at least one oxygen atom; R2A is —COR8 (wherein R8 is aryl); R3A is hydrogen or lower alkyl; and R12 represents cycloalkyl, aryl, aralkyl, alicyclic heterocyclic group, aromatic heterocyclic group, alicyclic hetocyclic-alkyl, or aromatic heterocyclic-alkyl, and R1A, R2A, R3A and R12 are individually optionally substituted.
摘要翻译: - 根据式(1A)的化合物,其中n为0至3的整数; R1A是含有至少一个氧原子的5元芳族杂环基; R2A是-COR8(其中R8是芳基); R3A是氢或低级烷基; R 12表示环烷基,芳基,芳烷基,脂环族杂环基,芳香族杂环基,脂环族环状烷基或芳香族杂环烷基,R1A,R2A,R3A,R12分别任选被取代,及其药学上可接受的盐。
-
公开(公告)号:US07880013B2
公开(公告)日:2011-02-01
申请号:US12766986
申请日:2010-04-26
IPC分类号: A61K31/427 , C07D417/14
CPC分类号: C07D417/06 , A61K31/427 , A61K31/438 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/5383 , A61K31/541 , A61K31/542 , A61K31/551 , A61K31/553 , A61K31/695 , C07D417/04 , C07D417/14 , C07D491/048 , C07D491/10 , C07D498/04 , C07D513/04
摘要: (Wherein n is an integer of from 0 to 3; R1 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, or a substituted or unsubstituted aromatic heterocyclic group; R2 is halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, —COR8, or the like; R3 and R4 may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, —COR12, or the like)For example, provided are adenosine A2A receptor antagonists comprising, as the active ingredient, a thiazole derivative represented by a general formula (I), or a pharmaceutically acceptable salt thereof, and the like.
摘要翻译: 本发明提供的腺苷A 2A受体拮抗剂包含作为活性成分的通式(I)所示的噻唑衍生物或其药学上可接受的盐等(其中,n为0〜3的整数,R1为 取代或未取代的环烷基,取代或未取代的芳基,取代或未取代的脂环族杂环基或取代或未取代的芳族杂环基; R2为卤素,取代或未取代的低级烷基,取代或未取代的芳基,取代或未取代的脂环族杂环基, 取代或未取代的芳族杂环基,-COR 8等; R 3和R 4可以相同或不同,各自表示氢原子,取代或未取代的低级烷基,取代或未取代的芳烷基,-COR 12等) 。
-
公开(公告)号:US20070105919A1
公开(公告)日:2007-05-10
申请号:US10584633
申请日:2004-12-24
申请人: Takao Nakajima , Masamori Sugawara , Shin-ichi Ushida , Tetsuji Ohno , Yuji Nomoto , Noriaki Uesaka , Yoshisuke Nakasato
发明人: Takao Nakajima , Masamori Sugawara , Shin-ichi Ushida , Tetsuji Ohno , Yuji Nomoto , Noriaki Uesaka , Yoshisuke Nakasato
IPC分类号: A61K31/427
CPC分类号: C07D417/06 , A61K31/427 , A61K31/438 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/5383 , A61K31/541 , A61K31/542 , A61K31/551 , A61K31/553 , A61K31/695 , C07D417/04 , C07D417/14 , C07D491/048 , C07D491/10 , C07D498/04 , C07D513/04
摘要: (Wherein n is an integer of from 0 to 3; R1 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, or a substituted or unsubstituted aromatic heterocyclic group; R2 is halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, —COR8, or the like; R3 and R4 may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, —COR12, or the like) For example, provided are adenosine A2A receptor antagonists comprising, as the active ingredient, a thiazole derivative represented by a general formula (I), or a pharmaceutically acceptable salt thereof, and the like.
摘要翻译: (其中n为0-3的整数; R 1是取代或未取代的环烷基,取代或未取代的芳基,取代或未取代的脂环族杂环基或取代或未取代的芳族杂环基; R 取代或未取代的芳基,取代或未取代的脂环族杂环基,取代或未取代的芳族杂环基,-COR 8或 R 3和R 4可以相同或不同,并且各自表示氢原子,取代或未取代的低级烷基,取代或未取代的芳烷基,-COR 3, 例如,提供了包含作为活性成分的由通式(I)表示的噻唑衍生物或腺苷A 2A受体拮抗剂的腺苷A 2A受体拮抗剂,或 药学上可接受的盐等。
-
公开(公告)号:US08273738B2
公开(公告)日:2012-09-25
申请号:US12440237
申请日:2007-09-05
申请人: Naoto Osakada , Mariko Osakada , Takashi Sawada , Satoshi Kaneko , Atsuko Mizutani , Noriaki Uesaka , Yoshisuke Nakasato , Keishi Katayama , Masamori Sugawara , Yushi Kitamura
发明人: Naoto Osakada , Mariko Osakada , Takashi Sawada , Satoshi Kaneko , Atsuko Mizutani , Noriaki Uesaka , Yoshisuke Nakasato , Keishi Katayama , Masamori Sugawara , Yushi Kitamura
IPC分类号: A61K31/535 , A61K31/4965
CPC分类号: C07D233/64 , C07D401/04 , C07D405/06 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04
摘要: A CB2 receptor modulator comprising an imidazole derivative represented by the general formula (I): [wherein, R1 represents optionally substituted lower alkyl or the like; R2 represents optionally substituted cycloalkyl or the like; R3 represents optionally substituted aryl or the like; and n represents an integer of 0 to 3] or a pharmaceutically acceptable salt thereof as an active ingredient, and the like are provided.
摘要翻译: 包含由通式(I)表示的咪唑衍生物的CB2受体调节剂:[其中,R 1表示任选取代的低级烷基等; R2代表任选取代的环烷基等; R3表示任选取代的芳基等; 和n表示0〜3的整数]或其药学上可接受的盐作为活性成分,等。
-
公开(公告)号:US20100152178A1
公开(公告)日:2010-06-17
申请号:US12440237
申请日:2007-09-05
申请人: Naoto Osakada , Mariko Osakada , Takashi Sawada , Satoshi Kaneko , Atsuko Mizutani , Noriaki Uesaka , Yoshisuke Nakasato , Keishi Katayama , Masamori Sugawara , Yushi Kitamura
发明人: Naoto Osakada , Mariko Osakada , Takashi Sawada , Satoshi Kaneko , Atsuko Mizutani , Noriaki Uesaka , Yoshisuke Nakasato , Keishi Katayama , Masamori Sugawara , Yushi Kitamura
IPC分类号: A61K31/5377 , C07D233/64 , A61K31/4174 , C07D401/04 , A61K31/4439 , C07D401/10 , A61K31/454 , C07D413/10 , C07D471/04 , A61K31/519 , C07D401/14 , A61K31/497 , C07D413/14 , A61P29/00 , A61P25/06 , A61P25/00 , A61P37/08 , A61P37/00 , A61P19/02 , A61P1/00 , A61P25/28 , A61P11/06 , A61P11/00 , A61P17/00 , A61P9/10 , A61P3/04 , A61P19/10 , A61P27/06
CPC分类号: C07D233/64 , C07D401/04 , C07D405/06 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04
摘要: A CB2 receptor modulator comprising an imidazole derivative represented by the general formula (I): [wherein, R1 represents optionally substituted lower alkyl or the like; R2 represents optionally substituted cycloalkyl or the like; R3 represents optionally substituted aryl or the like; and n represents an integer of 0 to 3] or a pharmaceutically acceptable salt thereof as an active ingredient, and the like are provided.
摘要翻译: 包含由通式(I)表示的咪唑衍生物的CB2受体调节剂:[其中,R 1表示任选取代的低级烷基等; R2代表任选取代的环烷基等; R3表示任选取代的芳基等; 和n表示0〜3的整数]或其药学上可接受的盐作为活性成分,等。
-
公开(公告)号:US20120289502A1
公开(公告)日:2012-11-15
申请号:US13558325
申请日:2012-07-25
申请人: Naoto Osakada , Mariko Osakada , Takashi Sawada , Satoshi Kaneko , Atsuko Mizutani , Noriaki Uesaka , Yoshisuke Nakasato , Keishi Katayama , Masamori Sugawara , Yushi Kitamura
发明人: Naoto Osakada , Mariko Osakada , Takashi Sawada , Satoshi Kaneko , Atsuko Mizutani , Noriaki Uesaka , Yoshisuke Nakasato , Keishi Katayama , Masamori Sugawara , Yushi Kitamura
IPC分类号: A61K31/4164 , A61P25/00 , A61K31/5377 , A61K31/4439 , A61K31/454
CPC分类号: C07D233/64 , C07D401/04 , C07D405/06 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04
摘要: A CB2 receptor modulator comprising an imidazole derivative represented by the general formula (I): [wherein, R1 represents optionally substituted lower alkyl or the like; R2 represents optionally substituted cycloalkyl or the like; R3 represents optionally substituted aryl or the like; and n represents an integer of 0 to 3] or a pharmaceutically acceptable salt thereof as an active ingredient, and the like are provided.
摘要翻译: 包含由通式(I)表示的咪唑衍生物的CB2受体调节剂:[其中,R 1表示任选取代的低级烷基等; R2代表任选取代的环烷基等; R3表示任选取代的芳基等; 和n表示0〜3的整数]或其药学上可接受的盐作为活性成分,等。
-
-
-
-
-
-
-
-
-